Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients
News
Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as ... Read more